SCHEMBL6702016

SCHEMBL6702016

Clc1nc2ccccc2c2c1ncn2CCOCc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.41
TLR7 Q9NYK1 2/20 0.41
ADORA2A P29274 2/20 0.41
POLB P06746 1/20 0.41
HRH2 P25021 1/20 0.41
ADRA1D P25100 1/20 0.41
HTR2A P28223 1/20 0.41
ADRA1A P35348 1/20 0.41
NUDT1 P36639 1/20 0.41
HTR2B P41595 1/20 0.41
PDE4D Q08499 1/20 0.41
KCNH2 Q12809 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
MCL1 Q07820 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
AGER Q15109 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6701764 0.84 LMNA (0.40) LMNATLR7ADORA2APOLBHRH2
SCHEMBL10737860 0.84 HTT (0.51) LMNATLR7ADORA2APOLBHRH2
SCHEMBL6701754 0.83 LMNA (0.39) LMNATLR7ADORA2APOLBHRH2
SCHEMBL9601993 0.82 CYP11B1 (0.50) LMNATLR7ADORA2APOLBHRH2
SCHEMBL9602030 0.80 TLR7 (0.47) LMNATLR7ADORA2APOLBHRH2
SCHEMBL2059407 0.80 TLR7 (0.54) LMNATLR7ADORA2APOLBHRH2
SCHEMBL6699766 0.79 SMN1; SMN2 (0.46) LMNAPOLBSMN1; SMN2MCL1CYP1A2
SCHEMBL9602816 0.78 SMN1; SMN2 (0.43) LMNATLR7ADORA2APOLBHRH2
SCHEMBL10587717 0.78 NPC1 (0.48) LMNATLR7ADORA2APOLBHRH2
SCHEMBL8126603 0.78 TLR7 (0.47) LMNATLR7ADORA2APOLBHRH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040072858-A1 Heterocyclic ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2004-04-15 US disclosed
US-6664260-B2 Viricides; anticarcinogneic agents; induction cytokine biosynthesis 3M INNOVATIVE PROPERTIES COMPANY 2003-12-16 US disclosed
US-20030065005-A1 Heterocyclic ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2003-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065005-A1 Heterocyclic ether substituted imidazoquinolines IFNG, IL2, IRF3 LMNA 3958/4885TLR7 35/4885ADORA2A 3459/4885
US-20040072858-A1 Heterocyclic ether substituted imidazoquinolines IFNG, IL2, IRF3 LMNA 3958/4885TLR7 35/4885ADORA2A 3459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.